

Lead Product(s) : Hydroconchinine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.
Details : S101 is a cell & gene therapy drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 24, 2025
Lead Product(s) : Hydroconchinine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
